Inhibitory metabolic drug interactions with newer psychotropic drugs: Inclusion in package inserts and influences of concurrence in drug interaction screening software;Interactions médicament-médicament par inhibition du métabolisme avec les nouveaux médicaments psychotropes: Leur inclusion dans les feuillets d'information et l'influence sur leur utilisation dans les logiciels de détection des interactions médicamenteuses

Annals of Pharmacotherapy

Volumn 46, Issue 10, 2012, Pages 1287-1298

  Boyce, Richard D ^a   Collins, Carol ^b   Clayton, Marc ^c   Kloke, John ^d   Horn, John R ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Drug information services; Drug interactions; Drug labeling; Psycho tropic

Indexed keywords

ALOSETRON; ALPRAZOLAM; AMFEBUTAMONE; CIMETIDINE; CITALOPRAM; CLOPIDOGREL; DESLORATADINE; DIGOXIN; DONEPEZIL; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; ITRACONAZOLE; LITHIUM; LORAZEPAM; MIRTAZAPINE; NEFAZODONE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PRASUGREL; PSYCHOTROPIC AGENT; RISPERIDONE; SELEGILINE; SERTRALINE; TERBINAFINE; TICLOPIDINE; UNINDEXED DRUG; VENLAFAXINE;

AREA UNDER THE CURVE; ARTICLE; COMPUTER PROGRAM; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFECT; DRUG INFORMATION; DRUG INTERACTION; DRUG MANUFACTURE; DRUG MARKETING; DRUG PACKAGING; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; METABOLIC INHIBITION; PHARMACOKINETICS; PRIORITY JOURNAL;

DRUG INTERACTIONS; HUMANS; PRODUCT LABELING; PSYCHOTROPIC DRUGS; SOFTWARE;

EID: 84867776378     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R150     Document Type: Article

References (109)

1. Dal-Ré R, Pedromingo A, García-Losa M, Lahuerta J, Ortega R. Are re-sults from pharmaceutical-company-sponsored studies available to the public? Eur J Clin Pharmacol 2010;66:1081-9. doi: 10.1007/s00228-010-0898-y
2. Hines LE, Ceron-Cabrera D, Romero K, et al. Evaluation of warfarin drug interaction listings in US product information for warfarin and in- teracting drugs. Clin Ther 2011;33:36-45.
3. Marroum PJ, Gobburu J. The product label: how pharmacokinetics and pharmacodynamics reach the prescriber. Clin Pharmacokinet 2002;41: 161-9. doi: 10.1016/j.clinthera.2011.01.021
4. Steinmetz KL, Coley KC, Pollock BG. Assessment of geriatric informa- tion on the drug label for commonly prescribed drugs in older people. J Am Geriatr Soc 2005;53:891-4. doi: 10.1111/j.1532-5415.2005.53273.x
5. Tulner LR, Frankfort SV, Gijsen GJPT, et al. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging 2008; 25:343-55. doi: 10.2165/00002512-200825040-00007
6. Gurwitz JH, Field TS, Judge J, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005; 118:251-8. doi: 10.1016/j.amjmed.2004.09.018
7. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug- drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-8. doi: 10.1001/jama.289.13.1652
8. Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid popula- tion. Pharmacotherapy 1998;18:1112-20.
9. Code of Federal Regulations Title 21. Washington DC: Food and Drug Administration, 2010. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=201.57 (accessed 7 Jun 2011).
10. Boyce RD, Handler SM, Karp JF, Hanlon JT. Age-related changes in an- tidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information. Am J Geriatr Pharmacother 2012;10:139-50. doi: 10.1016/j.amjopharm.2012.01.001
11. Spina E, de Leon J. Metabolic drug interactions with newer antipsy- chotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100: 4-22. doi: 10.1111/j.1742-7843.2007.00017.x
12. Spina E, Avenoso A, Salemi M, et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 2000;33:213-17. doi: 10.1055/s-2000-8361
13. Chermá M, Löfgren U, Almkvist G, Hallert C, Bengtsson F. Assessment of the prescription of antidepressant drugs in elderly nursing home pa- tients: a clinical and laboratory follow-up investigation. J Clin Psy-chopharmacol 2008;28:424-31. doi: 10.1097/JCP.0b013e31817d79eb
14. Med Lett Drugs Ther. http://medletter.org/ (accessed 2012 Apr 27).
15. Karkare SU, Bhattacharjee S, Kamble P, Aparasu R. Prevalence and pre- dictors of antidepressant prescribing in nursing home residents in the United States. Am J Geriatr Pharmacother 2011;9:109-19. doi: 10.1016/j.amjopharm.2011.03.001
16. Food and Drug Administration. Drugs@FDA database. www.accessdata.fda.gov/scripts/cder/drugsatfda/ (accessed 2011 Jun 7).
17. Physicians' desk reference 2010. 64th ed. Montvale NJ: Thomson, 2009.
18. FDA Guideline: drug interaction studies: study design, data analysis, and implications for dosing and labeling. Rockville, MD: Food and Drug Ad- ministration, 2006. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf (ac- cessed 2012 Feb 10).
19. Hansten PD, Horn JR. The top 100 drug interactions, a guide to patient management. Freeland, WA: H & H Publications, LLP; 2010.
20. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008;30:1206-27. doi: 10.1016/S0149-2918(08)80047-1
21. Landis JR, Koch GG. The measurement of observer agreement for cate- gorical data. Biometrics 1977;33:159-74. doi: 10.2307/2529310
22. Turpeinen M, Tolonen A, Uusitalo J, et al. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005;77:553-9. doi: 10.1016/j.clpt.2005.02.010
23. Farid NA, Payne CD, Ernest SC 2nd, et al. Prasugrel, a new thienopyri- dine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol 2008;48:53-9. doi: 10.1177/0091270007309709
24. Malling D, Poulsen MN, Søgaard B. The effect of cimetidine or omepra- zole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol 2005;60:287-90. doi: 10.1111/j.1365-2125.2005.02423.x
25. Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharma- okinet 2008;47:191-202. doi: 10.2165/00003088-200847030-00005
26. Skinner MH, Kuan H, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003;73:170-7. doi: 10.1067/mcp.2003.28
27. D'Souza DL, Dimmitt DC, Robbins DK, et al. Effect of alosetron on the pharmacokinetics of fluoxetine. J Clin Pharmacol 2001;41:455-8. doi: 10.1177/00912700122010177
28. Gupta S, Banfield C, Kantesaria B, Flannery B, Herron J. Pharmacokinet- ics/pharmacodynamics of desloratadine and fluoxetine in healthy volun-teers. J Clin Pharmacol 2004;44:1252-9. doi: 10.1177/0091270004269518
29. Sitsen JM, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol 2000;56:389-94. doi: 10.1007/s002280000174
30. Sitsen JM, Voortman G, Timmer CJ. Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J Psychopharmacol 2000;14:172-6. doi: 10.1177/026988110001400207
31. Ruwe FJL, Smulders RA, Kleijn HJ, Hartmans HLA, Sitsen JMA. Mir- tazapine and paroxetine: a drug-drug interaction study in healthy sub- jects. Hum Psychopharmacol 2001;16:449-59. doi: 10.1002/hup.318
32. Dockens RC, Greene DS, Barbhaiya RH. Assessment of pharmacokinet- ic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers. J Clin Pharmacol 1996;36:160-7.
33. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH. Coad- ministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam. J Clin Psychopharmacol 1995;15:409-16. doi: 10.1097/00004714-199512000-00004
34. Yasui-Furukori N, Saito M, Inoue Y, et al. Terbinafine increases the plas- ma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur J Clin Pharmacol 2007;63:51-6. doi: 10.1007/s00228-006-0217-9
35. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C. Selegi- line transdermal system: an examination of the potential for CYP450-de- pendent pharmacokinetic interactions with 3 psychotropic medications. J Clin Pharmacol 2007;47:146-58. doi: 10.1177/0091270006296151
36. Laine K, Anttila M, Heinonen E, et al. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharma- col 1997;20:419-33. doi: 10.1097/00002826-199710000-00006
37. Kivistö KT, Wang JS, Backman JT, et al. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 2001;57:37-42. doi: 10.1007/s002280100278
38. Laine K, Anttila M, Helminen A, Karnani H, Huupponen R. Dose linear- ity study of selegiline pharmacokinetics after oral administration: evi- dence for strong drug interaction with female sex steroids. Br J Clin Pharmacol 1999;47:249-54. doi: 10.1046/j.1365-2125.1999.00891.x
39. Nagy CF, Kumar D, Perdomo CA, et al. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharmacol 2004;58(suppl 1):25-33. doi: 10.1111/j.1365-2125.2004.01801.x
40. Troy SM, Rudolph R, Mayersohn M, Chiang ST. The influence of cime- tidine on the disposition kinetics of the antidepressant venlafaxine. J Clin Pharmacol 1998;38:467-74.
41. Lindh JD, Annas A, Meurling L, Dahl M, AL-Shurbaji A. Effect of keto- conazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol 2003;59:401-6. doi: 10.1007/s00228-003-0627-x
42. Hynninen V, Olkkola KT, Bertilsson L, et al. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin Pharmacol Ther 2008;83:342-8. doi: 10.1038/sj.clpt.6100311
43. Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administra- tion and CYP2D6 genotype on the pharmacokinetics of the new antipsy- chotic aripiprazole. Drug Metab Pharmacokinet 2005;20:55-64. doi: 10.2133/dmpk.20.55
44. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharma- cokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 2005;45:89-93. doi: 10.1177/0091270004269870
45. Gossen D, de Suray J, Vandenhende F, Onkelinx C, Gangji D. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002;4:E11. doi: 10.1208/ps040211
46. Wang C, Zhang Z, Li W, et al. The differential effects of steady-state flu- voxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol 2004;44:785-92. doi: 10.1177/0091270004266621
47. Berwaerts J, Cleton A, Herben V, et al. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharma-copsychiatry 2009;42:158-63. doi: 10.1055/s-0029-1202265
48. Thyssen A, Cleton A, Talluri K, et al. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psychopharmacol 2009;24:532-9. doi: 10.1002/hup.1049
49. Li K, Li X, Cheng Z, et al. Effect of erythromycin on metabolism of que- tiapine in Chinese suffering from schizophrenia. Eur J Clin Pharmacol 2005;60:791-5. doi: 10.1007/s00228-004-0853-x
50. Potkin SG, Thyrum PT, Alva G, et al. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002;22:121-30. doi: 10.1097/00004714-200204000-00004
51. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006;61:58-69. doi: 10.1111/j.1365-2125.2005.02507.x
52. Reyes JF, Preskorn SH, Khan A, et al. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assess- ment of pharmacokinetic changes and safety following multiple oral dos- es. Br J Clin Pharmacol 2004;58 (suppl 1):50-7. doi: 10.1111/j.1365-2125.2004.01817.x
53. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of risperidone. J Clin Pharmacol 1999;39:297-309.
54. Wilner KD, Hansen RA, Folger CJ, Geoffroy P. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol 2000;49 (suppl 1):57S-60S. doi: 10.1046/j.1365-2125.2000.00154.x
55. Miceli JJ, Smith M, Robarge L, Morse T, Laurent A. The effects of keto- conazole on ziprasidone pharmacokinetics-a placebo-controlled cross- over study in healthy volunteers. Br J Clin Pharmacol 2000;49 (suppl 1): 71S-6S. doi: 10.1046/j.1365-2125.2000.00156.x
56. Sanchez Garcia P, Carcas A, Zapater P, et al. Absence of an interaction between ibuprofen and zaleplon. Am J Health Syst Pharm 2000;57: 1137-41.
57. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and flu-conazole. Clin Pharmacol Ther 1998;64:661-71. doi: 10.1208/ps040211
58. Allard S, Sainati S, Roth-Schechter B, MacIntyre J. Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women. Drug Metab Dispos 1998;26:617-22.
59. Piergies AA, Sweet J, Johnson M, Roth-Schechter BF, Allard S. The ef- fect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1996;34:178-83.
60. Hulhoven R, Desager JP, Harvengt C, et al. Lack of interaction between zolpidem and H2antagonists, cimetidine and ranitidine. Int. J Clin Phar- macol Res 1988;8:471-76.
61. Luurila H, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the phar- macokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol 1998;54:163-6. doi: 10.1007/s002280050439
62. Saari TI, Laine K, Leino K, et al. Effect of voriconazole on the pharmacoki- netics and pharmacodynamics of zolpidem in healthy subjects. Br J Clin Pharmacol 2007;63:116-20. doi: 10.1111/j.1365-2125.2006.02707.x
63. Product information. Celexa tablet/solution (citalopram). St. Louis, MO: Forest Pharmaceuticals, February 2009.
64. Product information. Pristiq (desvenlafaxine) tablet, extended release for oral use. St. Louis, MO: Forest Pharmaceuticals, January 2009.
65. Product information. Cymbalta (duloxetine) capsule, delayed release. In- dianapolis, IN: Eli Lilly and Company, January 2010.
66. Product information. Lexapro (escitalopram) tablets/oral solution. St. Louis, MO: Forest Pharmaceuticals, March 2009.
67. Product information. Nefazodone tablet. North Wales, PA: Teva Pharma- ceuticals USA, August 2010.
68. Product information. Emsam (selegiline) patch. Napa, CA: Dey Pharma,LP. August 2009.
69. Product information. Sertraline tablet, film coated. Morgantown, WV: Mylan Pharmaceuticals, April 2010.
70. Product information. Effexor XR (venlafaxine) extended-release cap- sules. Madison, NJ: Wyeth, June 2009.
71. Product information. Abilify (aripiprazole) tablet/solution/injection, solu- tion. Rockville, MD: Otsuka America Pharmaceuticals, November 2009.
72. Product information. Saphris (asenapine) sublingual tablets. Roseland, NJ: Organon Pharmaceuticals USA, August 2009.
73. Product information. Fanapt (iloperidone) tablets. Rockville, MD: Vanda Pharmaceuticals, May 2009.
74. Product information. Zyprexa (olanzapine) tablet. Indianapolis, IN: Eli Lilly and Company, January 2010.
75. Product information. Invega (paliperidone) tablet, extended release. Ti- tusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, January 2010.
76. Product information. Seroquel (quetiapine). London, England: As- traZeneca, January 2009.
77. Product information. Geodon (ziprasidone) capsules/injection. New York, NY: Pfizer, June 2009.
78. Product information. Lunesta (eszopiclone) tablet, coated. Marlborough, MA: Sepracor Inc., June 2010.
79. Product information. Rozerem (ramelteon) tablet, film coated. Deerfield, IL: Takeda Pharmaceuticals North America, Inc, October 2008.
80. Product information. Zaleplon capsule. North Wales, PA: Teva Pharma- ceuticals USA, June 2008.
81. Product information. Ambien CR (zolpidem) extended-release tablets. Bridgewater, NJ,: Sanofi-aventis US, 2008.
82. Kustra R, Corrigan B, Dunn J, Duncan B, Hsyu PH. Lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion. J Clin Pharmacol 1999;39:1184-8.
83. Ketter TA, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995;15:327-33. doi: 10.1097/00004714-199510000-00004
84. Larsen F, Priskorn M, Overø KF. Lack of citalopram effect on oral digoxin pharmacokinetics. J Clin Pharmacol 2001;41:340-6. doi: 10.1177/00912700122010041
85. Gram LF, Hansen MG, Sindrup SH, et al. Citalopram: interaction stud- ies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993;15:18-24. doi: 10.1097/00007691-199302000-00003
86. Gutierrez M, Abramowitz W. Lack of effect of a single dose of keto- conazole on the pharmacokinetics of citalopram. Pharmacotherapy 2001;21: 163-8. doi: 10.1592/phco.21.2.163.34101
87. Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of thera-py-resistant depressive patients: a clinical, pharmacokinetic, and phar- macogenetic investigation. J Clin Psychopharmacol 1996;16:307-14. doi: 10.1097/00004714-199608000-00006
88. Nolting A, Abramowitz W. Lack of interaction between citalopram and the CYP3A4 substrate triazolam. Pharmacotherapy 2000;20:750-5. doi: 10.1592/phco.20.9.750.35198
89. Barbhaiya RH, Shukla UA, Greene DS, Breul HP, Midha KK. Investi- gation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharma- col 1996;16:26-34. doi: 10.1097/00004714-199602000-00005
90. Barbhaiya RH, Shukla UA, Greene DS. Lack of interaction between ne- fazodone and cimetidine: a steady state pharmacokinetic study in hu- mans. Br J Clin Pharmacol 1995;40:161-5.
91. Khan AY, Preskorn SH, Horst WD. Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study. J Pak Med Assoc 2007;57: 230-5.
92. Salazar DE, Marathe PH, Fulmor IE, Lee JS, Raymond RH, Uderman HD. Pharmacokinetic and pharmacodynamic evaluation during coad- ministration of nefazodone and propranolol in healthy men. J Clin Phar- macol 1995;35:1109-18.
93. Troy SM, Parker VD, Hicks DR, Boudino FD, Chiang ST. Pharmacoki- netic interaction between multiple-dose venlafaxine and single-dose lithium. J Clin Pharmacol 1996;36:175-81.
94. Product information. Clozapine tablet. Morgantown, WV: Mylan Phar- maceuticals, December 2009.
95. Potkin SG, Thyrum PT, Alva G, et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 2002;22:174-82. doi: 10.1097/00004714-200204000-00011
96. Product information. Wellbutrin (bupropion) tablet, film coated. Lon- don, England: SmithKline Beecham, August 2009.
97. Product information. Remeron soltab (mirtazapine) orally disintegrating tablets once-a-day. Kenilworth, NJ: Schering-Plough, March 2009.
98. Product information. Paxil (paroxetine) tablet, film coated. London, England: SmithKline Beecham, June 2010.
99. Product information. Risperdal (risperidone) tablets/oral solution. Ti- tusville, NJ: Janssen Pharmaceuticals, Inc., April 2010.
100. Ko Y, Malone DC, Skrepnek GH, et al. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal sur- vey of US prescribers. Drug Saf 2008;31:525-36. doi: 10.2165/00002018-200831060-00007
101. Chao SD, Maibach HI. Lack of drug interaction conformity in com- monly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol 2005;6:105-11. doi: 10.2165/00128071-200506020-00005
102. Anthony M, Romero K, Malone DC, et al. Warfarin interactions with substances listed in drug information compendia and in the FDA-ap-proved label for warfarin sodium. Clin Pharmacol Ther 2009;86:425-9. doi: 10.1038/clpt.2009.95
103. Fulda TR, Valuck RJ, Zanden JV, et al. Disagreement among drug com- pendia on inclusion and ratings of drug-drug interactions. Curr Ther Res Clin Exp 2000;61:540-8. doi: 16/S0011-393X(00)80036-3
104. Wang L, Wong M, Lightwood J, Cheng C. Black box warning con- traindicated comedications: concordance among three major drug inter- action screening programs. Ann Pharmacother 2010;44:28-34. doi: 10.1345/aph.1M475
105. Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm As- soc 2004;44:136-41. doi: 10.1331/154434504773062582
106. Olvey EL, Clauschee S, Malone DC. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin Pharmacol Ther 2010;87:48-51. doi: 10.1038/clpt.2009.198
107. Wong C, Ko Y, Chan A. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Ann Pharmacother 2008;42:1737-48. doi: 10.1345/aph.1L255
108. Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007;63:709-14. doi: 10.1111/j.1365-2125.2006.02809.x
109. FDA Guideline. In vivo drug metabolism/drug interaction studies-study de- sign, data analysis, and implications for dosing and labeling. Rockville, MD: Food and Drug Administration, 1999. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072119.pdf (accessed 2012 Feb 10).